+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Joint Pain Injections Market by Molecule Type, Indication, Route Of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Joint Pain Injections Market by Molecule Type, Indication, Route Of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Joint Pain Injections Market by Molecule Type, Indication, Route Of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4905012
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Joint Pain Injections Market grew from USD 5.04 billion in 2024 to USD 5.62 billion in 2025. It is expected to continue growing at a CAGR of 10.97%, reaching USD 9.43 billion by 2030.

Understanding the Evolving Landscape of Joint Pain Injections

Joint pain represents one of the most pervasive and challenging health concerns globally, imposing significant socioeconomic burdens on individuals and healthcare systems alike. As the population ages and the prevalence of chronic conditions such as osteoarthritis and rheumatoid arthritis continues to rise, the demand for effective, minimally invasive treatment modalities has never been higher. Injectable therapies have emerged at the forefront of this therapeutic revolution, offering clinicians the ability to deliver targeted relief directly to affected joints and soft tissues. These interventions range from traditional corticosteroid formulations to advanced biologics and synthetic polymers, each engineered to address pain, inflammation, and joint degeneration through unique mechanisms of action.

This executive summary synthesizes the latest developments in the joint pain injection market, highlighting evolving treatment paradigms, regulatory landscapes, and emerging competitive dynamics. By examining key drivers and barriers, this document equips decision-makers with the knowledge needed to navigate an increasingly complex environment. Whether you are a manufacturer seeking to optimize your product portfolio or a healthcare provider evaluating new treatment protocols, the insights presented herein will inform strategic planning and investment priorities for the coming years.

Transformative Shifts Reshaping Treatment and Delivery Models

Over the past decade, advancements in drug formulation and delivery technologies have transformed the joint pain injection landscape. Innovations in ultrasound-guided administration have enhanced precision, reducing procedural risk and improving clinical outcomes. Meanwhile, the emergence of platelet-rich plasma therapies has catalyzed a shift toward regenerative approaches, with growing evidence supporting tissue repair and long-term symptom relief. These transformative trends are further amplified by the integration of digital health platforms, enabling real-time monitoring of patient outcomes and adherence to follow-up regimens.

Simultaneously, manufacturers are exploring novel encapsulation techniques and sustained-release carriers to extend therapeutic effects and minimize repeat procedures. Regulatory agencies worldwide are adapting their frameworks to accommodate these complex biologics and combination products, streamlining approval pathways for therapies that demonstrate clear patient benefits. As stakeholders collaborate across clinical, regulatory, and technological domains, the market is poised for a new era of personalized joint care.

Assessing the Cumulative Impact of 2025 United States Tariffs

In 2025, newly implemented tariffs in the United States are exerting a cumulative influence on the joint pain injection supply chain. Duties levied on precursor chemicals and finished formulations have elevated raw material costs, prompting manufacturers to reassess sourcing strategies and negotiate revised supplier agreements. These changes have rippled through distribution networks, increasing unit costs for hospital pharmacies and specialty distributors alike.

Providers are responding by adjusting procurement practices and exploring domestic manufacturing options to mitigate exposure to import levies. Some suppliers have initiated cost-containment measures, including localized production of hyaluronic acid derivatives and corticosteroid injectables. Although these strategies entail upfront investments, they aim to stabilize pricing and safeguard access to essential therapies. As tariffs continue to shape market dynamics, stakeholders must remain vigilant and agile in managing supply chain complexities.

Deep Dive into Key Market Segmentation Insights

In-depth segmentation analysis reveals a multifaceted market defined by molecule, indication, administration route, end user, distribution channel, and patient age group. Among molecule types, corticosteroids dominate due to their rapid anti-inflammatory action, with formulations such as betamethasone, methylprednisolone acetate, and triamcinolone acetonide catering to diverse clinical needs. Hyaluronic acid injections, available in cross-linked and linear variants, offer viscoelastic support for joint lubrication, while platelet-rich plasma applications-both leukocyte-poor and leukocyte-rich-address regenerative objectives.

Indication segmentation highlights distinct management pathways for gout, osteoarthritis, and rheumatoid arthritis. Gout interventions encompass acute flare management and chronic prophylaxis, whereas osteoarthritis protocols target hip, knee, and shoulder joints with tailored viscosupplementation regimens. Rheumatoid arthritis injections are differentiated by large and small joint applications, reflecting variable dosing and formulation requirements. Routes of administration range from intra-articular techniques-conducted via landmark-based or ultrasound-guided methods-to intramuscular approaches in deep tissue and superficial settings, plus peri-articular injections that similarly leverage imaging guidance to optimize positioning.

End users span ambulatory surgical centers, hospitals, orthopedic clinics, and rheumatology clinics, each with unique procurement cycles and clinical workflows. Distribution channels include hospital pharmacy networks, online pharmacy platforms, retail pharmacy outlets, and specialty pharmacies that manage complex biologics. Patient demographics further segment the market into adolescents, adults, elderly, and pediatric cohorts, underscoring the need for age-appropriate formulations, dosing strategies, and safety profiles.

Unveiling the Regional Dynamics Shaping Market Growth

Regional analysis underscores divergent growth trajectories and strategic priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, robust healthcare infrastructure and high adoption rates of image-guided procedures support sustained demand for advanced injectables. Reimbursement frameworks in North America incentivize value-based care, encouraging providers to invest in therapies that reduce long-term costs and improve patient outcomes.

In Europe Middle East & Africa, market expansion is driven by public health initiatives aimed at addressing osteoarthritis among aging populations. Variability in regulatory pathways across jurisdictions necessitates agile compliance strategies, while emergent economies in the Gulf and North Africa present opportunities for localized manufacturing partnerships. Meanwhile, the Asia-Pacific region exhibits rapid growth fueled by increasing healthcare expenditure and rising awareness of minimally invasive interventions. Strategic collaborations between multinational manufacturers and regional distributors are crucial to navigate complex regulatory landscapes and diverse patient needs.

Spotlight on Leading Companies Driving Innovation

The competitive arena features established pharmaceutical and medical device firms alongside nimble biotech innovators. Leading companies have fortified their positions through strategic acquisitions, joint ventures, and robust research pipelines. Major players continue to refine corticosteroid portfolios while investing in next-generation hyaluronic acid platforms that promise extended durability and enhanced patient comfort.

At the same time, biotechnology firms specializing in platelet-rich plasma are forging collaborations with academic medical centers to validate regenerative protocols. Partnerships between imaging technology providers and injectable manufacturers are setting new standards for procedural accuracy and patient safety. Collectively, these corporate strategies are accelerating product lifecycle management and catalyzing the development of combination therapies that integrate anti-inflammatory and regenerative modalities.

Actionable Strategies for Industry Leaders to Stay Ahead

Industry leaders should prioritize investment in image-guided delivery solutions to differentiate their offerings and demonstrate superior clinical outcomes. Expanding portfolios to cover the full spectrum of indications-from acute gout management to chronic osteoarthritis care-will capture broader market share and meet growing patient expectations. Cultivating partnerships with specialty pharmacies and digital health platforms can streamline patient access and enhance adherence tracking.

Moreover, establishing regional manufacturing capabilities will mitigate tariff impacts and reinforce supply chain resilience. Companies should tailor distribution strategies to local market dynamics, leveraging hospital pharmacy networks in mature regions and online platforms in emerging economies. Finally, embracing precision medicine principles-such as age-specific formulations and biomarker-driven treatment algorithms-will position organizations at the forefront of personalized joint care.

Rigorous Research Methodology Ensuring Robust Insights

This research draws upon a rigorous methodology that integrates primary interviews with orthopedic surgeons, rheumatologists, and supply chain experts, alongside secondary analysis of peer-reviewed journals, regulatory filings, and proprietary databases. Data triangulation ensures the validity of market segmentation frameworks and regional insights. All inputs undergo systematic validation through expert panels and cross-referenced vendor agreements to maintain accuracy and reliability.

Quantitative data are complemented by qualitative assessments of emerging trends, with each finding subjected to a structured peer review process. This approach guarantees that conclusions are both evidence-based and actionable, providing stakeholders with the confidence to make informed strategic decisions.

Concluding Perspectives on the Future of Joint Pain Therapies

As joint pain injection therapies continue to evolve, the market is poised for sustained growth driven by technological innovation, expanding clinical evidence, and strategic collaborations. Personalized treatment protocols and integrated delivery platforms will redefine standards of care, while regional nuances in regulation and reimbursement will shape competitive dynamics.

Stakeholders who proactively address supply chain challenges, embrace advanced imaging modalities, and invest in targeted R&D will be best positioned to capitalize on emerging opportunities. Ultimately, a patient-centric approach-rooted in efficacy, safety, and long-term value-will underpin success in this dynamic and rapidly advancing sector.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Molecule Type
    • Corticosteroids
      • Betamethasone
      • Methylprednisolone Acetate
      • Triamcinolone Acetonide
    • Hyaluronic Acid
      • Cross-Linked
      • Linear
    • Platelet-Rich Plasma
      • Leukocyte-Poor
      • Leukocyte-Rich
  • Indication
    • Gout
      • Acute Management
      • Chronic Management
    • Osteoarthritis
      • Hip
      • Knee
      • Shoulder
    • Rheumatoid Arthritis
      • Large Joints
      • Small Joints
  • Route Of Administration
    • Intra-Articular
      • Landmark-Based
      • Ultrasound-Guided
    • Intramuscular
      • Deep Tissue
      • Superficial
    • Peri-Articular
      • Landmark-Based
      • Ultrasound-Guided
  • End User
    • Ambulatory Surgical Centers
    • Hospitals
    • Orthopedic Clinics
    • Rheumatology Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
    • Specialty Pharmacies
  • Patient Age Group
    • Adolescents
    • Adults
    • Elderly
    • Pediatrics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sanofi S.A.
  • Ferring Pharmaceuticals A/S
  • Zimmer Biomet Holdings, Inc.
  • Bioventus, Inc.
  • Seikagaku Corporation
  • Anika Therapeutics, Inc.
  • Teijin Pharma Limited
  • Fidia Farmaceutici S.p.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Joint Pain Injections Market, by Molecule Type
8.1. Introduction
8.2. Corticosteroids
8.2.1. Betamethasone
8.2.2. Methylprednisolone Acetate
8.2.3. Triamcinolone Acetonide
8.3. Hyaluronic Acid
8.3.1. Cross-Linked
8.3.2. Linear
8.4. Platelet-Rich Plasma
8.4.1. Leukocyte-Poor
8.4.2. Leukocyte-Rich
9. Joint Pain Injections Market, by Indication
9.1. Introduction
9.2. Gout
9.2.1. Acute Management
9.2.2. Chronic Management
9.3. Osteoarthritis
9.3.1. Hip
9.3.2. Knee
9.3.3. Shoulder
9.4. Rheumatoid Arthritis
9.4.1. Large Joints
9.4.2. Small Joints
10. Joint Pain Injections Market, by Route Of Administration
10.1. Introduction
10.2. Intra-Articular
10.2.1. Landmark-Based
10.2.2. Ultrasound-Guided
10.3. Intramuscular
10.3.1. Deep Tissue
10.3.2. Superficial
10.4. Peri-Articular
10.4.1. Landmark-Based
10.4.2. Ultrasound-Guided
11. Joint Pain Injections Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Orthopedic Clinics
11.5. Rheumatology Clinics
12. Joint Pain Injections Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
12.5. Specialty Pharmacies
13. Joint Pain Injections Market, by Patient Age Group
13.1. Introduction
13.2. Adolescents
13.3. Adults
13.4. Elderly
13.5. Pediatrics
14. Americas Joint Pain Injections Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Joint Pain Injections Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Joint Pain Injections Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Sanofi S.A.
17.3.2. Ferring Pharmaceuticals A/S
17.3.3. Zimmer Biomet Holdings, Inc.
17.3.4. Bioventus, Inc.
17.3.5. Seikagaku Corporation
17.3.6. Anika Therapeutics, Inc.
17.3.7. Teijin Pharma Limited
17.3.8. Fidia Farmaceutici S.p.A.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. JOINT PAIN INJECTIONS MARKET MULTI-CURRENCY
FIGURE 2. JOINT PAIN INJECTIONS MARKET MULTI-LANGUAGE
FIGURE 3. JOINT PAIN INJECTIONS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. JOINT PAIN INJECTIONS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. JOINT PAIN INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. JOINT PAIN INJECTIONS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY BETAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE ACETATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CROSS-LINKED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LINEAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-POOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LEUKOCYTE-RICH, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY CHRONIC MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HIP, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY KNEE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SHOULDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DEEP TISSUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SUPERFICIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY LANDMARK-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ULTRASOUND-GUIDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 94. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 95. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 96. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 97. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 98. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 100. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 101. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 102. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 104. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 105. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 106. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 109. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 112. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 113. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 115. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 117. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 119. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 120. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 121. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 185. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 188. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 189. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 191. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 192. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 193. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 195. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 196. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 197. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 201. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 202. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 203. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 204. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 206. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 207. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 208. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 210. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 211. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 212. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 231. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 232. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 233. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 234. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 236. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 237. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 238. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 240. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 241. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 242. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 245. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 246. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 247. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 248. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 249. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 250. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 251. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 252. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 253. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 255. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 256. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 257. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 282. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 286. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 290. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 292. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 294. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 296. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 298. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 300. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 302. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 304. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 305. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 306. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 307. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 308. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 309. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 310. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 311. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-2030 (USD MILLION)
TABLE 312. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 313. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY INTRA-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 315. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 316. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2030 (USD MILLION)
TABLE 317. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. DENMARK JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 320. NETHERLANDS JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 321. NETHERLANDS JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 322. NETHERLANDS JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS JOINT PAIN INJECTIONS MARKET SIZE, BY PLATELET-RICH PLASMA, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS JOINT PAIN INJECTIONS MARKET SIZE, BY GOUT, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS JOINT PAIN INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, 2018-

Companies Mentioned

The companies profiled in this Joint Pain Injections market report include:
  • Sanofi S.A.
  • Ferring Pharmaceuticals A/S
  • Zimmer Biomet Holdings, Inc.
  • Bioventus, Inc.
  • Seikagaku Corporation
  • Anika Therapeutics, Inc.
  • Teijin Pharma Limited
  • Fidia Farmaceutici S.p.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.62 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.43 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Sacroiliac Joint Fusion Injections and RF Ablation Market Size, Share & Trends Analysis Report by Indication (Degenerative Sacroiliitis, Sacral Disruption), Type (Diagnosis), End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Sacroiliac Joint Fusion Injections and RF Ablation Market Size, Share & Trends Analysis Report by Indication (Degenerative Sacroiliitis, Sacral Disruption), Type (Diagnosis), End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 150 Pages
  • Global
From
Joint Pain Injections - Global Strategic Business Report - Product Image

Joint Pain Injections - Global Strategic Business Report

  • Report
  • 378 Pages
  • Global
From
Joint Pain Injections Market Report 2025 - Product Image

Joint Pain Injections Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Joint Pain Injections Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Joint Pain Injections Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Sodium Hyaluronate Intra-Articular Injection Market by Indication, Product Type, End User, Distribution Channel, Frequency Of Administration - Global Forecast to 2030 - Product Image

Sodium Hyaluronate Intra-Articular Injection Market by Indication, Product Type, End User, Distribution Channel, Frequency Of Administration - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From

About the Joint Pain Injections Market

The Joint Pain Injections market is a subset of the Analgesics market, which is focused on providing relief from pain. Joint Pain Injections are used to treat pain caused by arthritis, bursitis, and other joint-related conditions. These injections are typically administered directly into the affected joint, and can provide relief from pain for several weeks or months. The Joint Pain Injections market is composed of a variety of products, including corticosteroids, hyaluronic acid, and platelet-rich plasma. These products are used to reduce inflammation, lubricate the joint, and promote healing. Some of the companies in the Joint Pain Injections market include Pfizer, Sanofi, and Novartis. Other companies include AbbVie, Merck, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.